Centre des tumeurs gynécologiques

Publications

Les intervenants du Centre des tumeurs gynécologiques publient chaque année les résultats de leurs travaux de recherches dans diverses revues suisses et internationales.

2017

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G

Ann Oncol. 2017 May 1;28(5):996-1004

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.

Monk BJ, Facciabene A, Brady WE, Aghajanian CA, Fracasso PM, Walker JL, Lankes HA, Manjarrez KL, Danet-Desnoyers GH, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G

Clin Cancer Res. 2017 Apr 15;23(8):1955-1966

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel.

Irving M, Vuillefroy de Silly R, Scholten K, Dilek N, Coukos G

Front Immunol. 2017;8:267

Radiotherapy combination opportunities leveraging immunity for the next oncology practice.

Herrera FG, Bourhis J, Coukos G

CA Cancer J Clin. 2017 Jan;67(1):65-85

2016

Neoantigen-based cancer immunotherapy.

Bobisse S, Foukas PG, Coukos G, Harari A

Ann Transl Med. 2016 Jul;4(14):262

Opportunities in immunotherapy of ovarian cancer.

Coukos G, Tanyi J, Kandalaft LE

Ann Oncol. 2016 Apr;27 Suppl 1:i11-i15

2015

Targeting Programmed Cell Death 1 in Ovarian Cancer.

Homicsko K, Coukos G

J Clin Oncol. 2015 Dec 1;33(34):3987-9

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki

Nat Rev Cancer. 2015 Nov;15(11):668-79

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G

Clin Cancer Res. 2015 Jun 15;21(12):2840-50

2014

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.

Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G

Nat Med. 2014 Jun;20(6):607-15

2013

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

Duraiswamy J, Freeman GJ, Coukos G

Cancer Res. 2013 Dec 1;73(23):6900-12

Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.

Simpkins F, Flores A, Chu C, Berek JS, Lucci J 3rd, Murray S, Bauman J, Struemper H, Germaschewski F, Jonak Z, Gardner O, Toso J, Coukos G

Cancer Immunol Res. 2013 Sep;1(3):168-78

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G

Clin Cancer Res. 2013 Sep 1;19(17):4801-15

Deciphering and reversing tumor immune suppression.

Motz GT, Coukos G

Immunity. 2013 Jul 25;39(1):61-73

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G

Oncoimmunology. 2013 Jan 1;2(1):e22664

2012

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Coukos G

J Transl Med. 2012 Aug 3;10:157

2011

Cancer immunotherapy comes of age.

Mellman I, Coukos G, Dranoff G

Nature. 2011 Dec 21;480(7378):480-9

The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Motz GT, Coukos G

Nat Rev Immunol. 2011 Sep 23;11(10):702-11

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Wal

Nat Rev Cancer. 2011 Sep 23;11(10):719-25

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G

Nature. 2011 Jul 13;475(7355):226-30